While the MRP of the device is Rs 37,380, Samsung Galaxy Note II is being sold at much lower prices on e-commerce portals.
There may be shortage of drugs till pharmaceutical companies supply new batches with revised MRPs.
Britannia, which last week announced a management rejig putting COO Varun Berry in charge of Indian operations, has always believed in quickly identifying new trends in the food and beverage segment.
Apollo Pharmacy, the country's largest branded drug retail network with over 1,500 outlets, has temporarily suspended sale of medicines manufactured by Ranbaxy Laboratories. It has also stopped further procurement from the company for now.
Says inordinate delay on this and other issues raised by firm earlier are impacting investor confidence.
The 2008 deal agreement contains provisions of arbitration to be held in that country.
Consultants are working with various teams on manufacturing, R&D, etc, to assess per-month productivity of each department.
The trouble-stricken company has sought appointment with at least two major hospitals -- Mumbai-based Jaslok and Gurgaon-based Medanta Medicity.
The company was indicted for violations at one of its US facilities in 2009, even after Daiichi Sankyo took over as majority shareholder in 2008.
The US FDA, during its inspection of Ranbaxy's manufacturing facilities in India, between 2006 and 2008, had found violations, incomplete testing records and an inadequate stability programme, besides manufacturing practices that did not follow regulations.
Patient safety and quality our guidance now, says CEO and MD Arun Sawhney.
Prime property rates in South Mumbai at Rs 60,000 a sq ft remain high despite a slowing realty market.
Singh says Japanese pharma giant's allegations false.
In what could be the beginning of fresh troubles for Ranbaxy Laboratories, which has just managed to settle long-pending issues with the US Department of Justice after agreeing to pay a penalty of $500 million, the health ministry in India, too, has decided to initiate a probe.
Last week, to study the market, Coca-Cola introduced promotional 750-ml PET bottles for Rs 30, the price point of 600-ml PET bottles, across its portfolio of Coke, Sprite, Thums Up, Fanta and Limca, primarily in metro cities.
Impending launch of Oral-B toothpaste in India, recent spate of product launches in other developing markets indicate shift in strategy.
Unlike their struggles elsewhere, Japanese majors Sony and Panasonic show no sign of fatigue in India, as consumers continue to lap up their products here.
Dinesh Thakur says he waved the red flag only after Ranbaxy didn't respond to his concerns.
The government is set to roll out an SMS-based helpline, which will enable consumers to seek information on various brands available in the market for their specific composition, with their prices.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances